Sandrine Roux
Lyon, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Efficacy and safety of dalbavancin as suppressive therapy in chronic implant-associated infections.
Journal: Infectious diseases now
Published: January 21, 2026
Risk factors of daptomycin overexposure: a case-control study.
Journal: Antimicrobial agents and chemotherapy
Published: November 07, 2025
Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series.
Journal: The Journal of antimicrobial chemotherapy
Published: April 26, 2025
Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for Candida infections.
Journal: Antimicrobial agents and chemotherapy
Published: September 26, 2024
Access to phage therapy at Hospices Civils de Lyon in 2022: Implementation of the PHAGEinLYON Clinic programme.
Journal: International journal of antimicrobial agents
Published: July 08, 2024
Isavuconazole off-label use as an empirical treatment of invasive fungal infections.
Journal: Annales pharmaceutiques francaises
Published: April 28, 2024
ANTIFON-CLIC®, a new clinical decision support system for the treatment of invasive aspergillosis: is it clinically relevant?
Journal: Annales pharmaceutiques francaises
Published: October 31, 2023
Impact of COVID-19 pandemic on antifungal consumption: a multicenter retrospective analysis.
Journal: Critical care (London, England)
Published: October 13, 2022
Practical checklist for implementation of antifungal stewardship programmes.
Journal: Journal of medical microbiology
Published: June 30, 2022
Necrotizing external otitis: analysis of relapse risk factors in 66 patients managed during a 12 year period.
Journal: The Journal of antimicrobial chemotherapy
Published: December 07, 2021
Implementation and Comparison of Two Pharmacometric Tools for Model-Based Therapeutic Drug Monitoring and Precision Dosing of Daptomycin.
Journal: Pharmaceutics
Published: November 15, 2021
Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study.
Journal: Open forum infectious diseases
Published: April 30, 2021
Last Updated: 09/26/2026